Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is an SEC Form 8-K “Current Report” filing under Item 8.01 (“Other Events”) disclosing interim clinical and biomarker data release via an oral presentation. It does not contain financial results or substantive financial statements, nor does it fit categories such as earnings release, management changes, capital actions, or M&A. It is a general regulatory announcement and thus falls into the fallback ‘Regulatory Filings’ category.
2026-05-26 English
DEF 14A - Gain Therapeutics, Inc. (0001819411) (Filer)
Proxy Solicitation & Information Statement
2026-04-28 English
4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
Director's Dealing
2026-03-27 English
4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
Director's Dealing
2026-03-27 English
8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Gain Therapeutics, Inc. It reports on a press release about presentations at a scientific conference (AD/PD 2026) and clinical study updates. The document includes no financial statements or detailed financial data, but rather disclosures of events and press releases. The length is 9472 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. The content is primarily event disclosure and regulatory compliance, typical of an 8-K filing. This type of filing is best classified under Regulatory Filings (RNS) as it does not fit into other categories like Annual Report, Earnings Release, or Management Reports, and is not a proxy, voting result, or capital update. Therefore, the appropriate classification is RNS with high confidence.
2026-03-18 English
8-K Filing
Investor Presentation Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 3, 2026, by Gain Therapeutics, Inc. It includes a reference to an Exhibit 99.1 which is an Investor Presentation. The text explicitly states that the Form 8-K is furnishing slides posted on the company's website to describe its business, and the exhibit is labeled as an Investor Presentation. The document length is 3967 characters, which is relatively short and consistent with a current report filing rather than a full financial report. The presence of the Form 8-K and the description of the exhibit as an Investor Presentation strongly indicates that this filing is an update to investors with a presentation rather than a full annual or quarterly report or other types of filings. Therefore, the correct classification is Investor Presentation (IP).
2026-02-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.